Experimental CAR T-Cell therapy takes on tough lymphoma
NCT ID NCT06534060
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This study tests an experimental treatment called MB-105 for people with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll about 46 adults and measure safety and how well the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Cleveland Clinic
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Moffitt Cancer Center Magnolia Campus
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregan Health & Science University
NOT_YET_RECRUITINGPortland, Oregon, 97239, United States
Contact
-
SCRI - Colorado Blood Cancer Institute (CBCI)
NOT_YET_RECRUITINGDenver, Colorado, 92037, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Nebraska
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of San Diego (UCSD)-Moores Cancer Center
RECRUITINGSan Diego, California, 92037, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MB-105 (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat T-cell lymphoma that has not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 46 participants, so results may not apply to everyone. CAR T-cell therapies can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.